Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Seibel

Showing results (71-80 of 489) with videos related to

Pageof 49
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 14, 2009
Use of bone turnover markers in the real world: are we there yet?Christian Meier, Markus J Seibel, Marius E Kraenzlin
The Journal of Clinical Endocrinology and Metabolism|November 7, 2003
Clinical review 165: Markers of bone remodeling in metastatic bone diseaseBerthold Fohr, Colin R Dunstan, Markus J Seibel
Clinical Chemistry|July 27, 2001
Interlaboratory variation of biochemical markers of bone turnoverM J Seibel, M Lang, W J Geilenkeuser
The Journal of Rheumatology|July 1, 1989
Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseasesM J Seibel, A Duncan, S P Robins
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 18, 2012
Selective glucocorticoid receptor agonists: glucocorticoid therapy with no regrets?Mark S Cooper, Hong Zhou, Markus J Seibel
Clinical Chemistry|November 1, 1996
Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseasesH W Woitge, M J Seibel, R Ziegler
Chemical Communications (Cambridge, England)|February 16, 2016
Synthesis of the rare disaccharide nigerose by structure-based design of a phosphorylase mutant with altered regioselectivityM Kraus, J Görl, M Timm, et al.
Endocrinology|June 17, 2004
Fibroblast growth factor 23: a phosphatonin regulating phosphate homeostasis?Colin R Dunstan, Hong Zhou, Markus J Seibel
Nature Clinical Practice. Oncology|December 22, 2006
Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone diseaseColin R Dunstan, Dieter Felsenberg, Markus J Seibel
The New England Journal of Medicine|May 14, 2010
Atypical femoral fractures and bisphosphonate useChristian M Girgis, Doron Sher, Markus J Seibel
Pageof 49

Showing results (71-80 of 489) with videos related to

Sort By:
Pageof 49
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 14, 2009
Use of bone turnover markers in the real world: are we there yet?Christian Meier, Markus J Seibel, Marius E Kraenzlin
The Journal of Clinical Endocrinology and Metabolism|November 7, 2003
Clinical review 165: Markers of bone remodeling in metastatic bone diseaseBerthold Fohr, Colin R Dunstan, Markus J Seibel
Clinical Chemistry|July 27, 2001
Interlaboratory variation of biochemical markers of bone turnoverM J Seibel, M Lang, W J Geilenkeuser
The Journal of Rheumatology|July 1, 1989
Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseasesM J Seibel, A Duncan, S P Robins
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 18, 2012
Selective glucocorticoid receptor agonists: glucocorticoid therapy with no regrets?Mark S Cooper, Hong Zhou, Markus J Seibel
Clinical Chemistry|November 1, 1996
Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseasesH W Woitge, M J Seibel, R Ziegler
Chemical Communications (Cambridge, England)|February 16, 2016
Synthesis of the rare disaccharide nigerose by structure-based design of a phosphorylase mutant with altered regioselectivityM Kraus, J Görl, M Timm, et al.
Endocrinology|June 17, 2004
Fibroblast growth factor 23: a phosphatonin regulating phosphate homeostasis?Colin R Dunstan, Hong Zhou, Markus J Seibel
Nature Clinical Practice. Oncology|December 22, 2006
Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone diseaseColin R Dunstan, Dieter Felsenberg, Markus J Seibel
The New England Journal of Medicine|May 14, 2010
Atypical femoral fractures and bisphosphonate useChristian M Girgis, Doron Sher, Markus J Seibel
Pageof 49